Wellbutrin News and Research

RSS

Wellbutrin is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder and for prevention of autumn-winter seasonal depression (seasonal affective disorder).

Anti-obesity drug Contrave may get another chance to prove itself

With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.

22 Sep 2011

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant Pharmaceuticals International, Inc. announces third quarter financial results for 2010. The merger of Biovail Corporation and Valeant Pharmaceuticals International was completed on September 28, 2010.

4 Nov 2010

Impax third quarter net income increases from $6.7 million to $75.2 million

Impax Laboratories, Inc. today reported adjusted net revenue in the third quarter of 2010, excluding the effect of a change in accounting for revenue received under the Company's Strategic Alliance Agreement with Teva, increased $42.6 million to $107.6 million compared to the prior year period, driven by sales of generic Adderall XR for which there were no sales in the third quarter of 2009, as well as increased sales of the Company's fenofibrate products.

2 Nov 2010

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL®.

1 Oct 2010

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail Corporation today announced financial results for the three-month and six-month periods ended June 30, 2010.

5 Aug 2010

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Impax Laboratories, Inc. today reported strong growth in the second quarter of 2010 due to an increase in sales from its Global Product sales channel. Total revenue increased $94.7 million to $153.1 million driven by continued strong sales of generic Adderall XR and generic Flomax for which there were no amounts in the second quarter of 2009, as well as increased sales of the Company's fenofibrate products.

3 Aug 2010

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Caraco Pharmaceutical Laboratories, Ltd. has started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). These bupropion hydrochloride extended release tablets, 100 mg, 150 mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

22 Jul 2010

Actavis Group receives FDA approval to market Bupropion HCl SR tablets

Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release tablets 100mg and 200mg. Distribution of the product will commence immediately.

22 Jul 2010

Combination therapy for severe depression

Severe depression is life threatening. So it is worth every effort to get depression under control and make life more manageable. For most people, that means some combination of antidepressant drugs and talk therapy.

29 Jun 2010

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail Corporation today announced its financial results for the three-month period ended March 31, 2010.

6 May 2010

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Impax Laboratories, Inc. today reported significant growth in the first quarter of 2010 due to an increase in sales from its Global product sales channel. Total revenue increased $264.4 million to $323.3 million driven by the successful March 2 exclusive launch of generic Flomax® ($176.2 million of revenue and $167.9 million of gross profit) and continued strong sales of generic Adderall XR® for which there were no comparable amounts in the first quarter 2009, as well as increased sales of the Company's fenofibrate products.

4 May 2010

American Lung Association's report examines lung cancer among African Americans

The American Lung Association today released its report, Too Many Cases, Too Many Deaths: Lung Cancer in African Americans, a compilation of research examining lung cancer among African Americans and the need to eliminate this and other health disparities.

13 Apr 2010

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.

13 Apr 2010

Mylan Pharmaceuticals' ANDA for generic Wellbutrin SR receives FDA final approval

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP, (SR), 100 mg, 150 mg and 200 mg, the generic version of GlaxoSmithKline's antidepressant Wellbutrin SR®.

12 Apr 2010

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets 100 mg/12.5 mg, the generic version of Merck and Co., Inc.'s antihypertensive Hyzaar®.

12 Apr 2010

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

Joseph F. Finn, Jr., C.P.A., Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties will be auctioned on May 28, 2010. The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors. He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.

12 Apr 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.

12 Apr 2010

Wellbutrin News and Research

Anti-obesity drug Contrave may get another chance to prove itself

Valeant third quarter revenue decreases 2% to $208.3 million

Impax third quarter net income increases from $6.7 million to $75.2 million

Mylan subsidiary launches Bupropion Hydrochloride Extended-release Tablets

Biovail second-quarter total revenues increase 23% to $238.8 million

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Actavis Group receives FDA approval to market Bupropion HCl SR tablets

Combination therapy for severe depression

Biovail reports 27% increase in first-quarter 2010 total revenues

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

American Lung Association's report examines lung cancer among African Americans

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Mylan Pharmaceuticals' ANDA for generic Wellbutrin SR receives FDA final approval

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News